Cardiovascular risk of BRCA1/2 mutation carriers: A review

L L M van Westerop; M Arts-de Jong; N Hoogerbrugge; J A de Hullu; A H E M Maas

doi:10.1016/j.maturitas.2016.06.012

Cardiovascular risk of BRCA1/2 mutation carriers: A review

Maturitas. 2016 Sep:91:135-9. doi: 10.1016/j.maturitas.2016.06.012. Epub 2016 Jun 22.

Authors

L L M van Westerop¹, M Arts-de Jong¹, N Hoogerbrugge², J A de Hullu¹, A H E M Maas³

Affiliations

¹ Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands, The Netherlands.
² Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands, The Netherlands.
³ Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands, The Netherlands. Electronic address: angela.maas@radboudumc.nl.

PMID: 27451331
DOI: 10.1016/j.maturitas.2016.06.012

Abstract

BRCA1/2 mutation carriers are at high risk of breast and ovarian cancer. The number of studies on non-cancer endpoints in BRCA1/2 mutation carriers is still limited. BRCA1/2 mutation carriers may be at higher cardiovascular risk due to early menopause after risk-reducing salpingo-oophorectomy and/or due to the potential cardiotoxic effects of breast cancer treatment (radiotherapy and chemotherapy). Moreover, BRCA genes have a role as a gatekeeper in cardiac function and structure, which may affect susceptibility to cardiac damage. Our goal is to review current knowledge of cardiovascular risk among BRCA1/2 mutation carriers.

Keywords: BRCA; Cardio-oncology; Cardiotoxicity; Cardiovascular disease; Salpingo-oophorectomy.

Publication types

Review

MeSH terms

BRCA1 Protein / genetics*
BRCA2 Protein / genetics*
Breast Neoplasms / complications
Breast Neoplasms / genetics*
Cardiovascular Diseases / epidemiology*
Cardiovascular Diseases / genetics
Female
Genetic Predisposition to Disease*
Humans
Mutation
Risk Factors
Risk Reduction Behavior
Women's Health

Substances

BRCA1 Protein
BRCA2 Protein